Table 1.
Normal (n=80) | Unobstructed CAD (n=88) | Unobstructed (n=168) | Obstructive CAD (n=83) | p Value | |
Age | 58.6±8.8 | 63.5±10.3 | 61.1±9.8 | 64.3±9.7 | 0.013 |
Sex (M:W) | 32:48 (40%) | 45:43 (51%) | 77:91 (46%) | 58:25 (70%) | <0.001 |
BMI | 30.3±5.4 | 30.8±5.7 | 30.4±5.5 | 30.0±7.0 | 0.59 |
Smoking (current) | 10 (12%) | 14 (16%) | 24 (14%) | 14 (17%) | 0.34 |
Hypercholesterol | 54 (68%) | 71 (81%) | 125 (74%) | 69 (83%) | 0.31 |
HTN | 40 (50%) | 40 (45%) | 90 (54%) | 43 (52%) | 0.82 |
DM | 12 (15%) | 29 (33%) | 41 (24%) | 16 (19%) | 0.19 |
FHx MI | 33 (42%) | 47 (53%) | 80 (48%) | 39 (47%) | 0.91 |
Antiplatelet use | 60 (75%) | 51 (58%) | 111 (66%) | 66 (78%) | 0.11 |
Aspirin | 58 | 34 | 92 | 57 | |
P2Y12 | 0 | 6 | 6 | 2 | |
Both | 2 | 11 | 13 | 7 | |
Statins | 50 (63%) | 50 (63%) | 109 (65%) | 66 (80%) | 0.045 |
All Caucasians but two. Other lowering lipid drugs: four ezetimibe and two fenofibrates.
BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; FHx MI, family history of stroke myocardial infarction; HTN, hypertension; M:W, men:women.